Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 2
---
the "Company"), no par value (the "common shares") by the selling shareholders identified in this prospectus (the "Selling Shareholders").

On August 29, 2025, the Company completed its previously announced acquisition of Antev Limited ("Antev") pursuant to that certain definitive securities exchange agreement, dated as of June 29, 2025 (as amended, the "Definitive Agreement"), by and among the Company, Antev and certain securityholders of Antev (the "Antev Vendors"), pursuant to which the Company acquired 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately $2.97 million in cash and 1,603,164 common shares of the Company (the "Consideration Shares") (the "Antev Transaction"). Certain of the Consideration Shares are the securities registered under the registration statement of which this prospectus forms a part.

We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our common shares by the Selling Shareholders. Information regarding the Selling Shareholders, the number of common shares that may be sold by them and the times and manner in which they may offer and sell the common shares under this prospectus is provided under the sections titled "Selling Shareholders" and "Plan of Distribution" on pages 149 and 155, respectively, of this prospectus. We have not been informed by the Selling Shareholders that they intend to sell their common shares offered by this prospectus and do not know when or in what amounts, if any, the Selling Shareholders may offer the common shares for sale. The Selling Shareholders may sell any, all, or none of the common shares offered by this prospectus.

Neither the Company nor any Selling Shareholders have any current arrangements nor have entered into any agreements with any underwriters, broker-dealers or selling agents for the sale of the common shares hereby registered.

Our common shares are listed on The Nasdaq Capital Market (the "Nasdaq"), under the symbol "MDCX". The closing price of our common shares on Nasdaq on September 26, 2025 was $2.63.

We are an "emerging growth company" and a "smaller reporting company" under applicable U.S. Securities and Exchange Commission ("SEC") rules and will be eligible for reduced public company disclosure requirements. See"Prospectus Summary-Implications of Being an Emerging Growth Company" and "Prospectus Summary